Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Suzanne M. Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Cecil Ross, Thomas Group, Jianxin Lin, Alain Luxembourg, Anuj Walia & Yingmei Tu. (2022) Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Zheng Quan Toh, Jennie Kosasih, Fiona M Russell, Suzanne M Garland, Edward K Mulholland & Paul V Licciardi. (2019) Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infection and Drug Resistance 12, pages 1951-1967.
Read now
Read now
Alain Luxembourg & Erin Moeller. (2017) 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Review of Vaccines 16:11, pages 1119-1139.
Read now
Read now
Brittany L. Rosen, Ralph DiClemente, Allie L. Shepard, Kelly L. Wilson & Sara K. Fehr. (2017) Factors associated with school nurses’ HPV vaccine attitudes for school-aged youth. Psychology, Health & Medicine 22:5, pages 535-545.
Read now
Read now
Articles from other publishers (14)
Vianney Tricou, Peter J. Winkle, Leslie M. Tharenos, Martina Rauscher, Ian Escudero, Elaine Hoffman, Inge LeFevre, Astrid Borkowski & Derek Wallace. (2023) Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults. Vaccine 41:47, pages 6999-7006.
Crossref
Crossref
Jaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, Julio C. Reina, Punnee Pitisuttithum, Angels Ulied, Linda-Gail Bekker, Edson D. MoreiraJrJr, Sven-Eric Olsson, Stan L. Block, Luciano S. Hammes, Fabio Laginha, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark Stoler, Oliver Bautista, Nancy E. Gallagher, Gino Salituro, Min Ye & Alain Luxembourg. (2023) Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics 152:4.
Crossref
Crossref
Ernest Hawk, Karen C. Maresso, Powel Brown, Michelle I. Savage & Scott M. Lippman. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
25
.
Megumi Kurosawa, Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J. B. Hanley, Megumi Hara, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Sayaka Ikeda, Asami Yagi & Takayuki Enomoto. (2022) Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. Vaccines 10:2, pages 256.
Crossref
Crossref
Jiao Tong, Chenxi Zhu, Hanyu Lai, Chunchao Feng & Dapeng Zhou. (2021) Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. Vaccines 9:3, pages 296.
Crossref
Crossref
Brahmana Askandar Tjokroprawiro. (2020) Intrauterine device and cervical cancer. Majalah Obstetri & Ginekologi 28:3, pages 140.
Crossref
Crossref
Sven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, Punnee Pitisuttithum, Angels Ulied, Meera Varman, Pierre Van Damme, Edson Duarte MoreiraJr.Jr., Daron Ferris, Stanley Block, Oliver Bautista, Nancy Gallagher, Jennifer McCauley & Alain Luxembourg. (2020) Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Research 10, pages 100203.
Crossref
Crossref
Brahmana Askandar. (2020) HPV vaccine development after more than ten years approval. Majalah Obstetri & Ginekologi 28:1, pages 39.
Crossref
Crossref
Ana M. Almeida, João A. Queiroz, Fani Sousa & Ângela Sousa. (2019) Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discovery Today 24:10, pages 2044-2057.
Crossref
Crossref
S M Garland, P Pitisuttithum, H Y S Ngan, C -H Cho, C -Y Lee, C -A Chen, Y C Yang, T -Y Chu, N -F Twu, R Samakoses, Y Takeuchi, T H Cheung, S C Kim, L -M Huang, B -G Kim, Y -T Kim, K -H Kim, Y -S Song, S Lalwani, J -H Kang, M Sakamoto, H -S Ryu, N Bhatla, H Yoshikawa, M C Ellison, S R Han, E Moeller, S Murata, M Ritter, M Sawata, C Shields, A Walia, G Perez & A Luxembourg. (2018) Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. The Journal of Infectious Diseases 218:1, pages 95-108.
Crossref
Crossref
Ángela María Ruiz-Sternberg, Edson D. MoreiraJrJr, Jaime A. Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C. Reina, Misoo C. Ellison, Erin Moeller, Michael Ritter, Christine Shields, Miguel Cashat, Gonzalo Perez & Alain Luxembourg. (2018) Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Research 5, pages 63-74.
Crossref
Crossref
C. SIGNORELLI, A. ODONE, V. CIORBA, P. CELLA, R. A. AUDISIO, A. LOMBARDI, L. MARIANI, F. S. MENNINI, S. PECORELLI, G. REZZA, G.V. ZUCCOTTI & A. PERACINO. (2017) Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiology and Infection 145:10, pages 1962-1982.
Crossref
Crossref
Brittany L. Rosen, Marcia L. Shew, Gregory D. Zimet, Lili Ding, Tanya L. K. Mullins & Jessica A. Kahn. (2017) Human Papillomavirus Vaccine Sources of Information and Adolescents’ Knowledge and Perceptions. Global Pediatric Health 4, pages 2333794X1774340.
Crossref
Crossref
Alba Lucía Cómbita, Tarik Gheit, Paula González, Devi Puerto, Raúl Hernando Murillo, Luisa Montoya, Alex Vorsters, Severien Van Keer, Pierre Van Damme, Massimo Tommasino, Gustavo Hernández-Suárez, Laura Sánchez, Rolando Herrero & Carolina Wiesner. (2016) Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. Cancer Prevention Research 9:9, pages 766-771.
Crossref
Crossref